# Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

> **NCT00453635** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 88 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Herceptin
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT00453635
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2012-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453635, "Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00453635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*